Clinical Trial Update: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase UCAR-T therapy targeting CD19/BCMA is being evaluated for relapsing or refractory multiple sclerosis, myasthenia gravis, CIDP, and autoimmune enc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Encephalitis
• Inflammatory Demyelinating Polyneuropathy
• Multiple Sclerosis
• Myasthenia Gravis

Drugs mentioned

• CD19/BCMA-Targeted UCAR-T

Snippet

Sponsor: Daishi Tian | Conditions: Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG) | EARLY_Phase 1 | Status: RECRUITING